

Address: Level 45, MLC Centre, 19 Martin Place, Sydney NSW 2000

www.azureht.com.au | Tel: +61 2 8279 8908

Azure Health Technology Limited trading as VGI Health Technology commences trading on National Stock Exchange

Sydney New South Wales, **28 May 2021** – The Directors are pleased to announce that the shares of Azure Health Technology Limited trading as VGI Health Technology (the **Company** or **VTL**) has commenced trading on the National Stock Exchange (NSX) with the ticker code NSX:VTL.

VTL will now launch it's patented nutraceutical products NE1-Elite® (for muscle sorness and muscle recovery after exercise) and NE1-Heart® (for maintenance of heart health) in the US. In addition, VTL will also advance the preparations for two Phase II clinical studies on Non-Alcoholic SteatoHepatitis (NASH) and pancreatic adenocarcinoma (pancreatic cancer), with one of these studies expected to commence recruitment of patients and commencement of dosing during the second half of 2021.

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant: https://www.nsx.com.au/broker_list_print.asp

For more information please contact:

Glenn Tong, CEO and Managing Director Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary Tel: +61 (0) 402 328 200

Andrew Crook, Investor and Media Relations Ph:+61 (0) 419 788 431

About Azure Health Technology Limited

Azure Health Technology Limited trading as VGI Health Technology is an Australian public biotechnology company listed on the National Stock Exchanbge (NSX) with the ticker code NSX:VTL. VTL is developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: https://www.azureht.com.au